#United States #New York #Securities Fraud #Pomerantz Law Firm #Gossamer Bio

Investor Alert: Gossamer Bio Class Action Lawsuit

In a significant development for investors, Pomerantz LLP has announced a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS). This legal action is vital for those who have incurred losses in their investments and are looking to seek justice.

Background of the Lawsuit

The class action lawsuit primarily addresses allegations of securities fraud and other unlawful business practices by Gossamer and certain officers within the company. Investors who purchased or acquired Gossamer securities during the Class Period might qualify for this action and are encouraged to take prompt steps to secure their rights.

Important Deadlines

Investors must be aware that they have until June 1, 2026, to request the court to appoint them as Lead Plaintiffs in this case. This is a crucial opportunity for affected shareholders to have their voices heard and potentially lead the lawsuit. Interested parties can obtain further details and a copy of the complaint via Pomerantz's website at www.pomerantzlaw.com.

Stock Performance Impact

This legal challenge comes after Gossamer's recent press release and conference call, where the company reported disheartening topline results from its Phase 3 PROSERA study assessing seralutinib for pulmonary arterial hypertension. The trial failed to meet its primary endpoint concerning improved six-minute walk distance at Week 24, with a failure to achieve the necessary statistical threshold. As a direct result of this disappointing news, Gossamer's stock plummeted by $1.71, equating to an 80.13% drop, closing at $0.42 per share on February 23, 2026.

About Pomerantz LLP

Founded by the infamous Abraham L. Pomerantz, recognized for establishing standards in class action law, Pomerantz LLP has a reputable track record in corporate, securities, and antitrust class litigation. With its presence across major cities like New York, Chicago, and Los Angeles, the firm continues to advocate for the rights of investors who have fallen victim to corporate misconduct. The firm has successfully secured millions in damages for class members in past litigations.

How to Get Involved

Investors affected by Gossamer's downturn are strongly urged to reach out to Pomerantz LLP. Interested parties should contact Danielle Peyton directly at [email protected] or via phone at 646-581-9980. It is recommended that those reaching out by email include their contact information and details about their share purchases to facilitate the process.

Conclusion

As this case unfolds, it represents a critical juncture for investors of Gossamer Bio. The implications of this class action may set precedents in how investor grievances are addressed concerning securities fraud and corporate accountability. As always, timely action will maximize the opportunity for affected parties to reclaim their lost investments.

Stay informed, engage with the materials available, and consider the potential benefits of participating in the class action lawsuit against Gossamer Bio.